OTC Regulatory Pathway Needs NDA Flexibility, Monograph Scope – Sharfstein
This article was originally published in The Pink Sheet Daily
Former FDA deputy commissioner Joshua Sharfstein, noting public health advocates’ disappointment with results from Sunscreen Innovation Act requirements, proposes an OTC drug review pathway that combines elements of the NDA and monograph systems and would require legislation to create.
You may also be interested in...
Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Ulta Working To Combat Surging Retail Theft As Q1 Sales Rise 12.3%
Ulta Beauty says consumers are being more selective in their spending but show “continued willingness to splurge and treat themselves.” The company is implementing additional mitigation strategies in its stores – including placing fragrances in locked cabinets – to combat organized retail theft that is expected to slightly reduce its operating margins for the full year.
E.l.f. Facing Off Against Beauty Giants: Third Among Mass Market Brands As Sales Jump 78%
E.l.f. cosmetics climbed to No. 3 brand in US mass market cosmetics, up two slots from a year ago as it surpassed Revlon and CoverGirl. In its recent sales and earnings presentation, it announced sales in its fiscal 2023 fourth quarter jumped 78%.